<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font26 { font-size : 26; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font26">the </span>
   <span class="font16">for </span>
   <span class="font16">with </span>
   <span class="font15">{background </span>
   <span class="font15">resistance </span>
   <span class="font14">was </span>
   <span class="font14">margin </span>
   <span class="font14">{border-style </span>
   <span class="font13">px;} </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">drug </span>
   <span class="font12">ART </span>
   <span class="font12">case </span>
   <span class="font12">patient </span>
   <span class="font12">HIV </span>
   <span class="font12">[], </span>
   <span class="font12">this </span>
   <span class="font12">HIV- </span>
   <span class="font12">GRT </span>
   <span class="font12">from </span>
   <span class="font12">The </span>
   <span class="font12">adherence </span>
   <span class="font12">all </span>
   <span class="font12">are </span>
   <span class="font11">Infect </span>
   <span class="font11">[]. </span>
   <span class="font11">clinical </span>
   <span class="font11">therapy </span>
   <span class="font11">viral </span>
   <span class="font11">mutations </span>
   <span class="font11">px; </span>
   <span class="font11">regimens </span>
   <span class="font11">resource-limited </span>
   <span class="font11">treatment </span>
   <span class="font11">virus </span>
   <span class="font11">{font-family </span>
   <span class="font11">August </span>
   <span class="font11">DTG </span>
   <span class="font11">antiretroviral </span>
   <span class="font11">been </span>
   <span class="font11">exposure </span>
   <span class="font11">font-size </span>
   <span class="font11">has </span>
   <span class="font11">have </span>
   <span class="font11">patients </span>
   <span class="font11">reported </span>
   <span class="font11">revealed </span>
   <span class="font11">were </span>
   <span class="font11">boosted </span>
   <span class="font11">double; </span>
   <span class="font11">first </span>
   <span class="font11">inhibitors </span>
   <span class="font11">integrase </span>
   <span class="font11">settings </span>
   <span class="font11">tropism </span>
   <span class="font11">which </span>
   <span class="font11">Africa </span>
   <span class="font11">Cameroon </span>
   <span class="font11">Commons </span>
   <span class="font11">Creative </span>
   <span class="font11">Following </span>
   <span class="font11">International </span>
   <span class="font11">Log </span>
   <span class="font11">RAMs </span>
   <span class="font11">after </span>
   <span class="font11">available </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">failing </span>
   <span class="font11">high-level </span>
   <span class="font11">including </span>
   <span class="font11">load </span>
   <span class="font11">management </span>
   <span class="font11">monitoring </span>
   <span class="font11">performed </span>
   <span class="font11">previous </span>
   <span class="font11">raltegravir </span>
   <span class="font11">regimen </span>
   <span class="font11">remains </span>
   <span class="font11">solid; </span>
   <span class="font11">third </span>
   <span class="font11">third-line </span>
   <span class="font11">transition </span>
   <span class="font11">use </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">CCR-tropic </span>
   <span class="font10">CD-cell </span>
   <span class="font10">Dolutegravir </span>
   <span class="font10">Health </span>
   <span class="font10">Integrase </span>
   <span class="font10">May </span>
   <span class="font10">NNRTI </span>
   <span class="font10">November </span>
   <span class="font10">RAL </span>
   <span class="font10">University </span>
   <span class="font10">Viral </span>
   <span class="font10">[â€"]. </span>
   <span class="font10">active </span>
   <span class="font10">al. </span>
   <span class="font10">associated </span>
   <span class="font10">bold </span>
   <span class="font10">but </span>
   <span class="font10">close </span>
   <span class="font10">consisting </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">dolutegravir </span>
   <span class="font10">em; </span>
   <span class="font10">failure </span>
   <span class="font10">implications </span>
   <span class="font10">inhibitor </span>
   <span class="font10">may </span>
   <span class="font10">might </span>
   <span class="font10">prior </span>
   <span class="font10">protease </span>
   <span class="font10">pt;} </span>
   <span class="font10">ritonavir </span>
   <span class="font10">showed </span>
   <span class="font10">testing </span>
   <span class="font10">therapeutic </span>
   <span class="font10">transcriptase </span>
   <span class="font10">under </span>
  </p>
 </body>
</html>
